On the eve of World Cancer Day 2015, amidst the ongoing cost-of-cancer-care debate, PACE (Patient Access to Cancer care Excellence), a Lilly Oncology initiative, is launching the PACE Continuous Innovation Indicators™ (CII). CII is the first evidence-based, customizable online tool to review progress against cancer over time—initially covering 12 cancer types. The purpose of the tool is to inform public policy reforms and other efforts to accelerate continuous innovation against cancer.
“We have seen tremendous progress in cancer treatment and care during the past decades, and continuous innovation, with one discovery building on another, is responsible for most of it,” said John C. Lechleiter, Ph.D., Chairman, President, and Chief Executive Officer of Eli Lilly and Company (NYSE:LLY). “To keep the momentum going, we need policies that support continuous innovation, but first we need a deeper understanding of the innovations that have occurred, and where we need to be.”
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7419451-eli-lilly-oncology-pace/
This week we bring you the tale of a less fortunate ending. Monty was a cute and lively dog that led a hard and difficult life. Recently Hong Kong Dog Rescue saved him from his abuse. But even with all the love and care he received from them his days were short lived. Sally Andersen, of Hong Kong Dog Rescue, reminds of us that we may not be able to save every troubled animal, but we should find it in our hearts to try.http://www.so-u.tv/playVideo.php?contestid=&id=1146
Nearly six of ten Americans will develop kidney disease in their lifetime, according to a new analysis published in the American Journal of Kidney Diseases. In comparison, lifetime risk of diabetes, heart attack and invasive cancer is approximately four in ten.
As a result of this and previous studies, the National Kidney Foundation is calling on healthcare professionals to screen patients in specific high-risk groups for kidney disease – those age 60 or older and those with high blood pressure or diabetes – by adding a simple urine albumin test for kidney damage to annual physical examinations.
To view the Multimedia News Release, go to http://www.multivu.com/mnr/62772-national-kidney-foundation-study-screening-for-disease
ACCU-CHEK Aviva Expert offers people with diabetes a new and easy way to simplify complex calculations to deliver precise insulin dosing advice.
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the ACCU-CHEK® Aviva Expert system, the first and only blood glucose meter system with a built-in insulin calculator to be approved by the U.S. Food and Drug Administration (FDA), is now available by prescription. The device represents a significant advancement in blood glucose meter technology for people with diabetes who take multiple daily insulin injections. The meter’s integrated bolus calculator provides easy-to-use and reliable dose recommendations based on automated calculations, eliminating the need for manual dosing calculations and estimations.
To view the Multimedia News Release, go to: http://www.multivu.com/players/English/7322751-roche-accu-chek-aviva-expert-blood-glucose-meter-now-available/
Sanofi Pasteur, the vaccines division of Sanofi (EURONEXT: SAN and NYSE: SNY), announced today the initiation of its Phase III clinical program called Cdiffense to evaluate the safety, immunogenicity and efficacy of an investigational vaccine for the prevention of primary symptomatic Clostridium difficile infection (CDI). Clostridium difficile (C. diff) is a potentially life-threatening, spore-forming bacterium that causes intestinal disease. The risk of C. diff increases with age, antibiotic treatment and time spent in hospitals or nursing homes, where multiple cases can lead to outbreaks. The investigational vaccine is designed to help protect at-risk individuals from C. diff, which is emerging as a leading cause of life-threatening, healthcare-associated infections (HAIs) worldwide.
To view the Multimedia News Release, go to http://www.multivu.com/mnr/62652-sanofi-pasteur-initiates-phase-iii-study-of-investigational-vaccine
According to recent survey by Medicomp Systems, 43 percent of healthcare IT professionals and physicians cited that their top data-related challenge was not a lack of data but rather the struggle to access the right data at the right time. Those findings aren't surprising since the vast majority of health information systems today share a common design flaw: they don't think and work the way physicians do at the point of care. However, they are still deeply concerning.
To deliver the best patient care, physicians need clinically relevant data that is seamlessly presented within their current workflows and integrated into the same workspace. The result is not only better patient care and better outcomes but also higher clinical effectiveness, efficiency, and satisfaction.
To view the multimedia release go to:
https://www.multivu.com/players/English/8189651-medicomp-systems-ebook-healthcare-data-challenges/
According to the 2010 Dietary Guidelines Advisory Committee, the majority of the American public is overfed or obese and yet under-nourished in several key nutrients¹. For people who try or want to maintain a healthy diet and lifestyle, but still lack key nutrients, it is important to seek the right vitamins from foods and select supplements from high-quality brands they can trust to fill this nutritional gap.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/naturemade/45299/
Nancy Lieberman, basketball hall of famer, coach and mom, has teamed up with Sanofi’s consumer healthcare division Chattem Inc. to introduce a new, more effective player on the over-the-counter (OTC) allergy medication roster, Nasacort Allergy 24HR Nasal Spray. Now available in stores nationwide, Nasacort Allergy 24HR is different than other currently available OTC allergy medications. It puts the “Full ‘Cort Press” on the full range of nasal allergy symptoms for 24 hours with a once daily dose. Nasacort Allergy 24HR is the first and only medicine in its class to be available at full prescription strength without the need for a prescription.
To view the Multimedia News Release, go to http://www.multivu.com/mnr/7122351-basketball-hall-of-famer-nancy-lieberman-nasacort-allergy-24hr
La beca para investigación sobre nutrición parenteral en América Latina ya está aceptando solicitudes.
La beca para investigación sobre nutrición parenteral en América Latina, que ha anunciado hoy la compañía internacional de cuidado de la salud Fresenius Kabi, se otorgará a una institución que cuente con un proyecto original directamente relacionado con el área terapéutica de nutrición clínica.
To view the multimedia release go to:
https://www.multivu.com/players/es-es/8261751-fresenius-kabi-financiar-nutricion/
Hundreds of CEOs from the healthcare, biotech and pharmaceutical industries plan to huddle next month with investment professionals to seek new business models to bridge healthcare’s gap between innovation and financial resources. They will be meeting at the 2nd Annual Global Leaders Healthcare Forum, in San Francisco on January 10, 2012. The forum is hosted by The Global Leaders, an exclusive business network of 2 million CEOs and other senior executives worldwide.
To view Multimedia News Release, go to http://www.multivu.com/mnr/53879-the-global-leaders-healthcare-forum-san-francisco-2011
Based on its recent analysis of the medical imaging market, Frost & Sullivan recognizes Siemens Healthcare with the 2011 North American Frost & Sullivan Award for New Product Innovation. Siemens Healthcare’s innovative Biograph mMR is the first scanner capable of simultaneously acquiring whole-body positron emission tomography (PET) and magnetic resonance imaging (MRI) data.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/frostsullivan/51015/
Sandaire, an international family investment office with a base in Singapore and Delancey, a UK focused real estate advisory company, today launch Mount Kendal in Asia. Mount Kendal is a new collaboration between Delancey and Sandaire and will be focused on delivering bespoke UK real estate investment advice to Asian investors and international family offices.
Together, the two firms bring over 45 years of experience to Mount Kendal, which was established to deliver acquisition strategies and innovative asset management initiatives. Ultimately Mount Kendal seeks to create and protect value across a myriad of multi-sector, single asset or asset portfolio investments; from office, retail, residential and logistics; to healthcare, education, equity reversions and more.
To view the multimedia release go to:
https://www.multivu.com/players/uk/8088051-sandaire-delancey-launch-mount-kendal/
